Skip to main content

Table 3 Response to treatment at 1 year

From: Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series

 

Overall (n = 15)

Initial therapy (n = 7)

Second-line therapy (n = 8)

Variable

Baseline

1-Year

P value

Baseline

1-Year

P value

Baseline

1-Year

P value

UPCR (g/g)

8.2 (6.6–11.1)

0.3 (0.2–0.7)

<0.001

6.9 (5.2–10.2)

0.2 (0.1–0.5)

0.02

10.1 (8–11.7)

0.6 (0.3–0.7)

0.01

Creatinine (mg/dL)

1.2 (0.8–1.5)

1.0 (0.8–1.2)

0.44

0.8 (0.5–0.9)

0.8 (0.7–1.0)

0.13

1.3 (1.2–2.1)

1.2 (1.1–1.7)

0.02

Albumin (mg/dL)

2.7 (2.5–2.8)

4.2 (4–4.4)

<0.001

2.7 (2.5–2.8)

4.2 (3.9–4.4)

0.02

2.6 (2.4–3.1)

4.2 (4.0–4.4)

0.01

Cholesterol (mg/dL)a

350 (252–371)

189 (148–220)

0.001

341 (252–367)

167 (128–191)

0.02

371 (249–438)

207 (155–251)

0.02

Triglycerides (mg/dL)

172 (122–270)

189 (148–220)

0.40

134 (77–192)

105 (80–244)

0.74

177 (155–546)

182 (152–204)

0.24

IgG (mg/dL)b

314 (199–551)

730 (538–908)

0.003

499 (296–731)

806 (676–1027)

0.02

199 (198–308)

611 (364–676)

0.08

  1. Data are presented as median (interquartile range). Baseline and 1 year values compared with Wilcoxon signed-rank test
  2. a1 patient in the second-line therapy group did not have baseline cholesterol or triglycerides
  3. bthree patients in the second-line therapy group had missing baseline IgG
  4. Abbreviations: IgG immunoglobulin G, UPCR urinary protein:creatinine ratio